InvestorsHub Logo
Followers 73
Posts 6211
Boards Moderated 0
Alias Born 05/01/2011

Re: jessellivermore post# 230763

Friday, 11/29/2019 8:16:28 AM

Friday, November 29, 2019 8:16:28 AM

Post# of 425680
Hey JL, have a look at this chart on MAT9001 (DPA):

MAT9001 trial vs Vascepa

Figure 3 struck me as familiar to what DHA does... gobbles up VLDL-C and turns it into bad stuff...

Keep in mind this was a 14-day trial, so you can't really see much from that, but you can see some minor LDL-C separation opening up between MAT9001 and Vascepa

“The trick is in what one emphasizes. We either make ourselves miserable, or we make ourselves happy. The amount of work is the same.” Carlos Castaneda

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News